NAMUSCLA新薬の考察と市場予測 - 2032年

当レポートでは、NAMUSCLA新薬の主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）について調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 筋強直性ジストロフィーにおけるNAMUSCLAの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（後期の新治療法）

第4章 NAMUSCLA市場の評価

• 筋強直性ジストロフィーにおけるNAMUSCLAの市場見通し
• 主要7市場の分析
  • 主要7市場の筋強直性ジストロフィー向けNAMUSCLAの市場規模
• 市場の分析：国別
  • 米国の筋強直性ジストロフィー向けNAMUSCLAの市場規模
  • ドイツの筋強直性ジストロフィー向けNAMUSCLAの市場規模
  • 英国の筋強直性ジストロフィー向けNAMUSCLAの市場規模

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: NAMUSCLA, Clinical Trial Description, 2023
• Table 2: NAMUSCLA, General Description
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: NAMUSCLA Market Size in the 7MM, in USD million (2019-2032)
• Table 5: NAMUSCLA Market Size in the US, in USD million (2019-2032)
• Table 6: NAMUSCLA Market Size in Germany, in USD million (2019-2032)
• Table 7: NAMUSCLA Market Size in France, in USD million (2019-2032)
• Table 8: NAMUSCLA Market Size in Italy, in USD million (2019-2032)
• Table 9: NAMUSCLA Market Size in Spain, in USD million (2019-2032)
• Table 10: NAMUSCLA Market Size in the UK, in USD million (2019-2032)
• Table 11: NAMUSCLA Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: NAMUSCLA Market Size in the 7MM, USD million (2019-2032)
• Figure 2: NAMUSCLA Market Size in the United States, USD million (2019-2032)
• Figure 3: NAMUSCLA Market Size in Germany, USD million (2019-2032)
• Figure 4: NAMUSCLA Market Size in France, USD million (2019-2032)
• Figure 5: NAMUSCLA Market Size in Italy, USD million (2019-2032)
• Figure 6: NAMUSCLA Market Size in Spain, USD million (2019-2032)
• Figure 7: NAMUSCLA Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: NAMUSCLA Market Size in Japan, USD million (2019-2032)

“"NAMUSCLA (Mexiletine) Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about NAMUSCLA for Myotonic Dystrophy in the seven major markets. A detailed picture of the NAMUSCLA for myotonic dystrophy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NAMUSCLA for myotonic dystrophy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NAMUSCLA market forecast analysis for myotonic dystrophy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myotonic dystrophy.

Drug Summary:

NAMUSCLA (Mexiletine) is a generic cardiovascular drug, initially developed to treat heart rhythm abnormalities, and holds some potential for treating muscle stiffness and other symptoms of non-dystrophic myotonias (NDMs). Myotonic dystrophy has as one of its alterations abnormal function of the chloride channel. This causes myotonia and stiffness, and, like the patients with non-dystrophic myotonia, myotonic dystrophy patients show a beneficial response to treatment with NAMUSCLA. Mexiletine slows the rate of movement of sodium ions into muscle cells, reducing or eliminating the tendency of the muscle to maintain a prolonged contraction. This enables the muscle cell to relax properly and prepare for the next contraction. In addition, the US FDA has granted NAMUSCLA ODD to treat myotonic dystrophy. Furthermore, the company is currently conducting two Phase III trials in myotonic dystrophy patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the NAMUSCLA description, mechanism of action, dosage and administration, research and development activities in myotonic dystrophy.
• Elaborated details on NAMUSCLA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the NAMUSCLA research and development activities in myotonic dystrophy across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around NAMUSCLA.
• The report contains forecasted sales of NAMUSCLA for myotonic dystrophy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myotonic dystrophy.
• The report also features the SWOT analysis with analyst views for NAMUSCLA in myotonic dystrophy.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NAMUSCLA Analytical Perspective by DelveInsight

In-depth NAMUSCLA Market Assessment

This report provides a detailed market assessment of NAMUSCLA for myotonic dystrophy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

NAMUSCLA Clinical Assessment

The report provides the clinical trials information of NAMUSCLA for myotonic dystrophy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for myotonic dystrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NAMUSCLA dominance.
• Other emerging products for myotonic dystrophy are expected to give tough market competition to NAMUSCLA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NAMUSCLA in myotonic dystrophy.
• Our in-depth analysis of the forecasted sales data of NAMUSCLA from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NAMUSCLA in myotonic dystrophy.

Key Questions:

• What is the product type, route of administration and mechanism of action of NAMUSCLA?
• What is the clinical trial status of the study related to NAMUSCLA in myotonic dystrophy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NAMUSCLA development?
• What are the key designations that have been granted to NAMUSCLA for myotonic dystrophy?
• What is the forecasted market scenario of NAMUSCLA for myotonic dystrophy?
• What are the forecasted sales of NAMUSCLA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to NAMUSCLA for myotonic dystrophy?
• Which are the late-stage emerging therapies under development for the treatment of myotonic dystrophy?

Table of Contents

1. Report Introduction

2. NAMUSCLA Overview in myotonic dystrophy

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. NAMUSCLA Market Assessment

• 4.1. Market Outlook of NAMUSCLA in myotonic dystrophy
• 4.2. 7MM Analysis
  • 4.2.1. Market Size of NAMUSCLA in the 7MM for myotonic dystrophy
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market Size of NAMUSCLA in the United States for myotonic dystrophy
  • 4.3.2. Market Size of NAMUSCLA in Germany for myotonic dystrophy
  • 4.3.3. Market Size of NAMUSCLA in France for myotonic dystrophy
  • 4.3.4. Market Size of NAMUSCLA in Italy for myotonic dystrophy
  • 4.3.5. Market Size of NAMUSCLA in Spain for myotonic dystrophy
  • 4.3.6. Market Size of NAMUSCLA in the United Kingdom for myotonic dystrophy
  • 4.3.7. Market Size of NAMUSCLA in Japan for myotonic dystrophy

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options